Delivery Order SPE2DB24D1007-SPE2DB25FCCWM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,179.32 to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5mL) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order, issued without set-aside designation, reflects a competitively awarded transaction under the company's broader pharmaceutical supply relationship with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5ML) with a ceiling value of $8,254.21 under a firm fixed-price contract type. The award was made on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This is a competitively awarded, non-set-aside delivery order issued under...
- The Defense Logistics Agency awarded a delivery order valued at $15,903.80 to AmerisourceBergen Drug Corp for the supply of Menquadfi vials (0.5ML) on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $7,484.58 to AmerisourceBergen Drug Corp for MENQUADFI vial 0.5ML on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price contract represents a pharmaceutical supply delivery to be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation and falls under a delivery order contract type,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for pharmaceutical supplies, specifically MENQUADFI vial 0.5ML, with a ceiling value of $1,452.88. This delivery order utilizes a firm fixed price contract type and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $2,905.76 to AmerisourceBergen Drug Corp for MENQUADFI vials (0.5mL) on August 14, 2025, with completion targeted for August 15, 2025. This firm fixed-price delivery order represents a non-competitive child award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $1 billion ceiling through December 2026. The product will be performed at the contractor's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,358.64 to AmerisourceBergen Drug Corp for the supply of MENQUADFI vials (0.5ML) under a firm fixed-price contract type. The award, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive delivery order without set-aside provisions. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of MENQUADFI vial 0.5ML, a meningococcal vaccine product. The contract is valued at $2,179.32 with a firm fixed price structure and an ultimate completion date of July 30, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a $1,452.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Menquadfi vial 0.5ml, a meningococcal vaccine product. The contract was competitively awarded with no set-aside designation and is scheduled for completion by August 12, 2025. AmerisourceBergen will perform work from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The $1,404.96 contract is for the supply of MENQUADFI VIAL 0.5ML, a pharmaceutical product, with a completion date of February 1, 2024. This delivery order is part of a larger $999,999,999.00 indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FCCWMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,656.00 to AmerisourceBergen Drug Corp for the supply of Menquadfi vials (0.5mL) on August 18, 2025, with a completion date of August 19, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract under AmerisourceBergen's larger federal contract vehicle. The place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and primary distribution hub for federal pharmaceutical procurement. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum value of $999,999,999.00 and extends through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceuticals and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a significant portfolio of federal contract awards with DLA and other government agencies, consistently fulfilling medical procurement requirements through competitive selection and demonstrating capability to serve defense and veteran healthcare systems across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 8/18/25 |